FORA Capital LLC Acquires New Shares in GSK plc (NYSE:GSK)

FORA Capital LLC bought a new position in shares of GSK plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 32,531 shares of the pharmaceutical company’s stock, valued at approximately $1,100,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Indiana Trust & Investment Management Co raised its holdings in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in shares of GSK during the fourth quarter valued at about $26,000. ST Germain D J Co. Inc. raised its stake in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the period. Sierra Ocean LLC purchased a new position in shares of GSK during the 4th quarter worth approximately $32,000. Finally, Parkside Financial Bank & Trust increased its holdings in GSK by 470.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock valued at $34,000 after purchasing an additional 818 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 0.7 %

Shares of NYSE:GSK opened at $36.63 on Friday. The stock has a market cap of $75.58 billion, a price-to-earnings ratio of 23.04, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The firm’s 50 day moving average price is $37.65 and its 200 day moving average price is $36.00. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business had revenue of $10.06 billion during the quarter, compared to analysts’ expectations of $7.52 billion. During the same period in the prior year, the firm posted $0.43 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a dividend yield of 4.60%. The ex-dividend date is Friday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 86.60%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, BNP Paribas began coverage on shares of GSK in a report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and a consensus target price of $40.58.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.